Review



cgas activator  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    InvivoGen cgas activator
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Cgas Activator, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 669 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgas activator/product/InvivoGen
    Average 97 stars, based on 669 article reviews
    cgas activator - by Bioz Stars, 2026-02
    97/100 stars

    Images

    1) Product Images from "Genomic stress drives activation of interferon signaling and innate immune pathways during SMA Type II myoblasts differentiation"

    Article Title: Genomic stress drives activation of interferon signaling and innate immune pathways during SMA Type II myoblasts differentiation

    Journal: bioRxiv

    doi: 10.64898/2025.12.23.696216

    A) Scheme of treatment of control myoblasts with cGAS agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Figure Legend Snippet: A) Scheme of treatment of control myoblasts with cGAS agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.

    Techniques Used: Control, Expressing, Enzyme-linked Immunosorbent Assay



    Similar Products

    cgas activation  (MedChemExpress)
    94
    MedChemExpress cgas activation
    Cgas Activation, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgas activation/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    cgas activation - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    cgas activator  (InvivoGen)
    97
    InvivoGen cgas activator
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Cgas Activator, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgas activator/product/InvivoGen
    Average 97 stars, based on 1 article reviews
    cgas activator - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    cgas sting pathway activation  (Boster Bio)
    93
    Boster Bio cgas sting pathway activation
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Cgas Sting Pathway Activation, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgas sting pathway activation/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    cgas sting pathway activation - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    antibodies for investigating the activation of the cgas-sting signaling axis  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc antibodies for investigating the activation of the cgas-sting signaling axis
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Antibodies For Investigating The Activation Of The Cgas Sting Signaling Axis, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies for investigating the activation of the cgas-sting signaling axis/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    antibodies for investigating the activation of the cgas-sting signaling axis - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    pd drug name source identifier drug target known function cgamp selleckchem s7904 sting agonist activates cgas sting pathway  (Selleck Chemicals)
    93
    Selleck Chemicals pd drug name source identifier drug target known function cgamp selleckchem s7904 sting agonist activates cgas sting pathway
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Pd Drug Name Source Identifier Drug Target Known Function Cgamp Selleckchem S7904 Sting Agonist Activates Cgas Sting Pathway, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd drug name source identifier drug target known function cgamp selleckchem s7904 sting agonist activates cgas sting pathway/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    pd drug name source identifier drug target known function cgamp selleckchem s7904 sting agonist activates cgas sting pathway - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    vitro cgas activity assay recombinant human cgas  (MedChemExpress)
    94
    MedChemExpress vitro cgas activity assay recombinant human cgas
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Vitro Cgas Activity Assay Recombinant Human Cgas, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vitro cgas activity assay recombinant human cgas/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    vitro cgas activity assay recombinant human cgas - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    potent inhibitor of human cgas activity (ic50 =)  (Pfizer Inc)
    90
    Pfizer Inc potent inhibitor of human cgas activity (ic50 =)
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Potent Inhibitor Of Human Cgas Activity (Ic50 =), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/potent inhibitor of human cgas activity (ic50 =)/product/Pfizer Inc
    Average 90 stars, based on 1 article reviews
    potent inhibitor of human cgas activity (ic50 =) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    catabolite gene activator (cga  (Agilent technologies)
    90
    Agilent technologies catabolite gene activator (cga
    A) Scheme of treatment of <t>control</t> <t>myoblasts</t> with <t>cGAS</t> agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.
    Catabolite Gene Activator (Cga, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/catabolite gene activator (cga/product/Agilent technologies
    Average 90 stars, based on 1 article reviews
    catabolite gene activator (cga - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A) Scheme of treatment of control myoblasts with cGAS agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.

    Journal: bioRxiv

    Article Title: Genomic stress drives activation of interferon signaling and innate immune pathways during SMA Type II myoblasts differentiation

    doi: 10.64898/2025.12.23.696216

    Figure Lengend Snippet: A) Scheme of treatment of control myoblasts with cGAS agonist during the myoblast differentiation process (n=3 independent treatments). B) Representative image of control myoblasts treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. C) Quantification of the fusion index of control treated with lipofectamine (mock) or cGAS agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. *p<0.01. D) Maturation index of control myoblasts treated with lipofectamine (mock) or agonist after 3 days of differentiation. Means were tested using a one-way ANOVA test. n.s. not significant. E) Quantification of cGAS agonist-treated myotube area. Means were tested using a one-way ANOVA test. ****p<0.00001. F) Quantification of cGAS agonist-treated myotube width. Means were tested using a one-way ANOVA test. **p<0.001. G) Quantification of cGAS agonist-treated myotube length. Means were tested using a one-way ANOVA test. *p<0.01. H) qPCR for IFNB expression in cGAS agonist-treated myotubes. Means were tested using a one-way ANOVA test. *p<0.01. I) ELISA measurement of IFNB secretion by cGAS agonist-treated and mock myotubes. Means were tested using a one-way ANOVA test. n.s. not significant.

    Article Snippet: Myoblasts were transfected at 80% confluence with 1mg/mL cGAS activator (2’3’-cGAMP Invivogen #tlrl-nacga23-02) using Lipofectamine 2000 (Invitrogen) in differentiation media according to the manufacturer’s instructions.

    Techniques: Control, Expressing, Enzyme-linked Immunosorbent Assay